

## MATERIAL CHANGE REPORT

### PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

Luminor Medical Technologies Inc. (formerly Miraculins Inc.) (the "Company")  
6 – 1250 Waverley Street  
Winnipeg, Manitoba  
R3T 6C6

2. **Date of Material Change:**

April 21, 2016

3. **News Release:**

The Company issued a press release regarding the material change on April 21, 2016, a copy of which is attached hereto.

4. **Summary of Material Change:**

On April 21, 2016, the Company announced the appointment of Christian Sauvageau as the Company's new President & CEO. Christopher J. Moreau has stepped down in his role as President & CEO of the Company, and as a member of its board of directors, effective today.

5. **Full Description Of Material Change:**

See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

7. **Omitted Information:**

Not Applicable.

8. **Executive Officer:**

Chris Carmichael, Chief Financial Officer  
Tel: (647) 225-4337

DATED at Winnipeg, Manitoba this 1<sup>st</sup> day of May, 2016.

**LUMINOR MEDICAL TECHNOLOGIES INC.**

Per:                     *“Chris Carmichael”*                      
Chris Carmichael, CFO

## **SCHEDULE “A”**

### **Pharma Executive Christian Sauvageau Appointed New CEO of Luminor Medical Technologies (Formerly Miraculins)**

**WINNIPEG, Manitoba – April 21, 2016** – Luminor Medical Technologies Inc. (TSX-V:LMT) (the “Company” or “Luminor”) (formerly Miraculins Inc.), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces the appointment of Christian Sauvageau as the Company’s new President & CEO. Christopher J. Moreau has stepped down in his role as President & CEO of the Company, and as a member of its board of directors, effective today. Mr. Moreau will stay on as a consultant and will work closely with Mr. Sauvageau in order to ensure that there is a full and proper transition.

“The board wishes to recognize Chris Moreau’s outstanding vision and determination for the last nine years in his role as President & Chief Executive Officer and we are grateful to him for his focused leadership, integrity and extraordinary personal commitment through many challenging years and difficult capital markets,” said Harry Bloomfield QC, chairman of the Luminor board.

“I have been extremely proud over the years to have worked with a truly dedicated group of staff, professionals, consultants, board members and investors, all of whom have shared a common vision of advancing the unique and meaningful medical technologies we acquired towards commercialization and greater beneficial health throughout the world. I wish Christian and all our stakeholders great success in the next phase of the Company’s journey,” said Christopher Moreau.

Prior to joining Luminor, Mr. Sauvageau founded his consulting firm, CSCG Inc., where he supported a select number of start-up and medical technology companies. Prior to starting CSCG Inc. in 2014, Mr. Sauvageau was Vice President of the Customer Innovation Business Unit at Merck Canada Ltd where he introduced innovative products and practices and contributed to the EUCAN Beyond the Pill strategy. During his 29 years of experience, Mr. Sauvageau also held senior sales, marketing, and business development positions at Merck & Co. He has national and international experience and has been instrumental in launching major brands in multiple therapeutic areas in addition to driving successful transformation activities.

Mr. Sauvageau graduated with a B.Sc.(Biochemistry) from University Laval in Quebec, Canada and was an Officer of the Canadian Armed Forces. Christian combined a high degree of ethics and integrity to a passion for patient health and business results.

“Christian Sauvageau brings significant expertise in sales, marketing and business development from his many years of working in the pharma sector. His vision and leadership skills will be a great asset for Luminor as we move through the next phase in our development”, said Harry Bloomfield QC, chairman of the Luminor board

#### **About Luminor Medical Technologies Inc.**

Luminor Medical Technologies Inc. is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. The Company’s Scout DS<sup>®</sup> device has been regulatory cleared in certain markets as a clinical tool to assist in the identification of both prediabetes and type 2 diabetes, and is the first non-invasive testing system designed to provide a highly sensitive and convenient method for measuring prediabetes and type 2 diabetes related biomarkers in the skin, the accumulation of which are accelerated by abnormal blood sugar levels and oxidative stress. Unlike current testing methods, a Scout DS<sup>®</sup> test requires no blood draw, no fasting, and no waiting for a lab result. The product has been used and validated in thousands of patients around the world.

For more information visit [www.miraculins.com](http://www.miraculins.com) or contact:

Luminor Medical Technologies Inc.  
Chris Carmichael  
CFO  
Ph. 647.225.4337

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Scout DS<sup>®</sup> is a registered trademark of Luminor Medical Technologies Inc. All Rights Reserved. 2016.*